ifn-α-7

Resiquimod (R848) is an agonist of Toll-like receptors 7 and 8 (TLR7/TLR8) that induces the upregulation of cytokines including TNF-α, IL-6, and IFN-α. It possesses immunomodulatory, antitumor, and antiviral activities, and can be used to induce models of myocarditis and systemic lupus erythematosus (SLE).

TLR7 agonist21 (Compound 27B) is a selective activator of Toll-like receptor 7 (TLR7), with an EC50 of 17.53 nM for human TLR7 and 41.7 nM for mouse TLR7. It induces the secretion of pro-inflammatory cytokines, including IL-6, TNF-α, IFN-α1, and IL-4. Acting as a vaccine adjuvant, TLR7 agonist21 enhances IgG and IgA levels, offering protection for mice against influenza virus infection.

KOR agonist 7 (Compound 29) is a highly selective κ-opioid receptor (KOR) agonist with a Ki of 138 nM. It shows no activity on μ and δ opioid receptors or the σ1 receptor, and exhibits very low affinity for the σ2 receptor (Ki = 2.8 μM). This compound significantly reduces the secretion of pro-inflammatory cytokines, such as IL-6, TNF-α, and IFN-γ, while increasing the secretion of the anti-inflammatory cytokine IL-10. Additionally, KOR agonist 7 decreases the expression of pro-inflammatory M1 macrophage marker (CD80) and increases the expression of anti-inflammatory M2 macrophage marker (CD163). It can be utilized for pain relief and immunomodulation.

Anti-TLR7 Antibody is a humanized monoclonal antibody targeting Toll-like receptor 7 (TLR7). TLR7 is a pattern recognition receptor primarily located on endosomal membranes that recognizes single-stranded RNA (ssRNA), playing a pivotal role in antiviral immune responses and autoimmune diseases such as Systemic Lupus Erythematosus (SLE). This antibody specifically binds to TLR7, blocking its activation by ligands (e.g., viral RNA or synthetic agonists) and subsequently inhibiting the downstream MyD88-dependent signaling pathway and the production of Type I interferons (IFN-α/β). By modulating TLR7 signaling, Anti-TLR7 Antibody serves as a valuable tool for investigating viral infection mechanisms and therapeutic strategies for autoimmune disorders.